“The Alberta case marks the second VITT case and only death related to VITT out of more than 253,000 doses of AstraZeneca or CoviSHIELD/AstraZeneca that have been administered in Alberta to date.”
An Alberta woman in her 50s has died after receiving the AstraZeneca COVID-19 vaccine, according to the province’s chief medical officer of health.
In a news release issued Tuesday night, Dr. Deena Hinshaw said the fatality was confirmed to be linked to “vaccine-induced immune thrombotic thrombocytopenia (VITT).”
The National Advisory Council on Immunization estimates VITT occurs at a rate of 1 in 100,000 shots. As of Monday, there were seven reported cases of VITT in Canada and just one other death, a 54 year old women from Quebec.
Hinshaw said the risk of COVID-19 is far greater than the risk of VITT.
"Albertans 50 to 59 who are diagnosed with COVID-19 are 350 times more likely to die from that infection than to experience VITT after an AstraZeneca vaccine," she said in the statemen
Health Canada has said the AstraZeneca vaccine meets its strict safety standards, and that it continues to monitor adverse outcomes to ensure the benefits of the vaccine outweigh risks.